NO2760821T3 - - Google Patents

Info

Publication number
NO2760821T3
NO2760821T3 NO12780535A NO12780535A NO2760821T3 NO 2760821 T3 NO2760821 T3 NO 2760821T3 NO 12780535 A NO12780535 A NO 12780535A NO 12780535 A NO12780535 A NO 12780535A NO 2760821 T3 NO2760821 T3 NO 2760821T3
Authority
NO
Norway
Application number
NO12780535A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2760821T3 publication Critical patent/NO2760821T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO12780535A 2014-01-31 2012-08-31 NO2760821T3 (US07585860-20090908-C00136.png)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461933948P 2014-01-31 2014-01-31

Publications (1)

Publication Number Publication Date
NO2760821T3 true NO2760821T3 (US07585860-20090908-C00136.png) 2018-03-10

Family

ID=52484569

Family Applications (1)

Application Number Title Priority Date Filing Date
NO12780535A NO2760821T3 (US07585860-20090908-C00136.png) 2014-01-31 2012-08-31

Country Status (23)

Country Link
US (3) US20170057961A1 (US07585860-20090908-C00136.png)
EP (1) EP3099688B1 (US07585860-20090908-C00136.png)
JP (1) JP6419836B2 (US07585860-20090908-C00136.png)
CN (1) CN106459051B (US07585860-20090908-C00136.png)
AR (1) AR099228A1 (US07585860-20090908-C00136.png)
BR (1) BR112016016741B1 (US07585860-20090908-C00136.png)
CA (1) CA2937738C (US07585860-20090908-C00136.png)
CY (1) CY1120534T1 (US07585860-20090908-C00136.png)
DK (1) DK3099688T3 (US07585860-20090908-C00136.png)
EA (1) EA032650B1 (US07585860-20090908-C00136.png)
ES (1) ES2655540T3 (US07585860-20090908-C00136.png)
HR (1) HRP20172002T1 (US07585860-20090908-C00136.png)
HU (1) HUE038060T2 (US07585860-20090908-C00136.png)
LT (1) LT3099688T (US07585860-20090908-C00136.png)
MX (1) MX2016009385A (US07585860-20090908-C00136.png)
NO (1) NO2760821T3 (US07585860-20090908-C00136.png)
PL (1) PL3099688T3 (US07585860-20090908-C00136.png)
PT (1) PT3099688T (US07585860-20090908-C00136.png)
RS (1) RS56785B1 (US07585860-20090908-C00136.png)
SI (1) SI3099688T1 (US07585860-20090908-C00136.png)
TW (1) TWI703144B (US07585860-20090908-C00136.png)
UY (1) UY35972A (US07585860-20090908-C00136.png)
WO (1) WO2015116882A1 (US07585860-20090908-C00136.png)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625256T3 (es) 2011-10-14 2017-07-19 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
SG11201606209PA (en) 2014-01-31 2016-08-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (US07585860-20090908-C00136.png) 2014-01-31 2018-03-10
JP6526796B2 (ja) 2014-09-04 2019-06-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｆｘｉａ阻害剤であるジアミドマクロ環
NO2721243T3 (US07585860-20090908-C00136.png) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors
ES2803659T3 (es) * 2015-07-29 2021-01-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor xia que contienen restos alquilo o cicloalquilo p2’
US10676477B2 (en) 2015-07-29 2020-06-09 Bristol-Myers Squibb Company Factor XIa macrocycle inhibitors bearing a non-aromatic P2' group
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
EP3368036B1 (en) * 2015-10-29 2022-07-20 Merck Sharp & Dohme LLC Macrocyclic pyridine-n-oxide derivatives as factor xia inhibitors
CN109195973A (zh) 2016-03-02 2019-01-11 百时美施贵宝公司 具有因子xia抑制活性的二酰胺大环类化合物
US10143681B2 (en) 2016-08-22 2018-12-04 Merck Sharp & Dohme Corp. Factor XIa inhibitors
WO2018095953A1 (de) 2016-11-23 2018-05-31 Bayer Cropscience Aktiengesellschaft 2-[3-(alkylsulfonyl)-2h-indazol-2-yl]-3h-imidazo[4,5-b]pyridin-derivate und ähnliche verbindungen als schädlingsbekämpfungsmittel
CN110312718B (zh) 2017-01-10 2023-02-28 拜耳公司 作为害虫防治剂的杂环烯衍生物
MX2019008229A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
CN110922412A (zh) * 2018-09-20 2020-03-27 复旦大学 具有抗精神病作用药物化合物的不对称合成方法
AU2020257911B2 (en) * 2019-04-16 2023-01-05 China Resources Biopharmaceutical Company Limited Macrocyclic derivatives acting as XIa factor inhibitor
EP4006029A4 (en) * 2019-07-23 2023-06-21 Medshine Discovery Inc. MACROCYCLIC DERIVATIVES AS FACTOR XIA INHIBITORS
WO2022222960A1 (zh) * 2021-04-21 2022-10-27 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
EP0028489B1 (en) 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU717298B2 (en) 1996-04-03 2000-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
NZ528282A (en) 1998-03-19 2005-05-27 Vertex Pharma Interleukin-1 beta converting enzyme inhibitors
CN1138778C (zh) 1998-05-26 2004-02-18 沃尼尔·朗伯公司 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
EP1140878A1 (en) 1999-01-02 2001-10-10 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them ( inhibitio of factor xa activity )
TR200102913T2 (tr) 1999-04-09 2002-01-21 Basf Aktiengesellschaft Tam proteazların düşük moleküler ağırlıklı inhibitörleri.
CA2383008A1 (en) 1999-06-14 2000-12-21 Amanda Jane Lyons Compounds
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
AU5959201A (en) 2000-05-11 2001-11-20 Bristol Myers Squibb Co Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AU2002322802A1 (en) 2001-07-27 2003-02-17 Merck And Co., Inc. Thrombin inhibitors
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
UA78232C2 (uk) 2001-09-21 2007-03-15 Брістол-Майерс Сквібб Компані Лактамвмісні сполуки та їх похідні як інгібітори фактора ха
US6649606B1 (en) 2001-11-09 2003-11-18 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003106438A1 (en) 2002-06-18 2003-12-24 The Scripps Research Institute Synthesis of diazonamide "a" core
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
JP2007501844A (ja) 2003-08-08 2007-02-01 トランス　テック　ファーマ，インコーポレイテッド アリール及びヘテロアリール化合物、組成物並びに使用方法
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
WO2007047608A2 (en) 2005-10-14 2007-04-26 Epix Pharmaceuticals, Inc. Fibrin targeted therapeutics
KR20080067697A (ko) 2005-11-11 2008-07-21 에프. 호프만-라 로슈 아게 응고 인자 ｘａ의 억제제로서 카보사이클릭 융합된사이클릭 아민
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
WO2007070826A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
JP2009519966A (ja) 2005-12-14 2009-05-21 ブリストル−マイヤーズ スクイブ カンパニー セリンプロテアーゼ阻害剤として有用な６員ヘテロ環
PE20071132A1 (es) 2005-12-23 2007-12-14 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
ES2546815T3 (es) 2006-12-15 2015-09-28 Bristol-Myers Squibb Company Análogos de arilpropilamida, arilacrilamida, arilpropinamida o arilmetilurea como inhibidores del factor XIa
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
MX2009012847A (es) 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
CN102026996B (zh) 2008-03-13 2015-01-07 百时美施贵宝公司 作为凝血因子xia抑制剂的哒嗪衍生物
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
EP2534152B1 (en) * 2010-02-11 2018-05-02 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US9161924B2 (en) 2011-07-08 2015-10-20 Merck Sharp & Dohme Corp. Factor IXa inhibitors
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
EP2899183B1 (en) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Substituted Tetrahydroisoquinoline Compounds as Factor Xia Inhibitors
ES2625256T3 (es) 2011-10-14 2017-07-19 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
EP3290413B9 (en) 2011-12-21 2020-04-29 ONO Pharmaceutical Co., Ltd. Pyridinone and pyrimidinone derivatives as factor xia inhibitors
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
CA2881566A1 (en) 2012-07-19 2014-01-23 Yohei Ikuma 1-(cycloalkyl-carbonyl)proline derivative
AU2013296258A1 (en) * 2012-08-03 2015-03-19 Bristol-Myers Squibb Company Dihydropyridone P1 as factor XIa inhibitors
TW201410667A (zh) * 2012-08-03 2014-03-16 必治妥美雅史谷比公司 二氫吡啶酮ｐ１作爲凝血因子ｘｉａ抑制劑
US9403774B2 (en) 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014059203A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059202A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014120346A1 (en) 2012-12-19 2014-08-07 Merck Sharp & Dohme Corp. Factor ixa inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CA2918814C (en) 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
WO2015044170A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
US20160280699A1 (en) 2013-09-26 2016-09-29 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
US20160237045A1 (en) 2013-09-26 2016-08-18 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
US20160237067A1 (en) 2013-09-26 2016-08-18 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
WO2015044165A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
EP3049407A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate als faktor xia modulatoren
WO2015044167A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate als faktor xia modulatoren
WO2015044163A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
WO2015047973A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
US20160257668A1 (en) 2013-10-07 2016-09-08 Merck Sharp & Dohme Corp. Factor XIa Inhibitors
JP6337750B2 (ja) 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
AU2014378428A1 (en) 2014-01-14 2016-09-01 Sumitomo Dainippon Pharma Co., Ltd. Condensed 5-oxazolidinone derivative
SG11201606209PA (en) 2014-01-31 2016-08-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
NO2760821T3 (US07585860-20090908-C00136.png) 2014-01-31 2018-03-10
CN108892661B (zh) 2014-02-07 2023-03-14 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
EP3104701B1 (en) 2014-02-11 2019-01-30 Merck Sharp & Dohme Corp. Factor xia inhibitors
EP3138839B1 (en) 2014-02-14 2020-10-28 Sichuan Haisco Pharmaceutical Co., Ltd. Pyridone or pyrimidone derivative, preparation method therefor and application thereof
EP4180424A1 (en) 2014-03-07 2023-05-17 BioCryst Pharmaceuticals, Inc. Substituted pyrazoles as human plasma kallikrein inhibitors
WO2015160634A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
US9969724B2 (en) 2014-04-16 2018-05-15 Merck Sharp & Dohme Corp. Factor IXa inhibitors
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
RU2016150410A (ru) 2014-05-28 2018-06-28 Мерк Шарп И Доум Корп. Ингибиторы фактора xia
ES2712886T3 (es) 2014-09-24 2019-05-16 Bayer Pharma AG Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
NO2721243T3 (US07585860-20090908-C00136.png) 2014-10-01 2018-10-20
AU2015362422B2 (en) 2014-12-10 2019-11-14 Ono Pharmaceutical Co., Ltd. Dihydroindolizinone derivative
US10160750B2 (en) 2015-06-19 2018-12-25 Bristol-Myers Squibb Company Diamide macrocycles as factor XIa inhibitors

Also Published As

Publication number Publication date
US20180222907A1 (en) 2018-08-09
US20170342071A1 (en) 2017-11-30
HRP20172002T1 (hr) 2018-02-09
TW201615640A (zh) 2016-05-01
CA2937738C (en) 2023-01-17
SI3099688T1 (sl) 2017-12-29
EA201691561A1 (ru) 2017-01-30
RS56785B1 (sr) 2018-04-30
ES2655540T3 (es) 2018-02-20
PT3099688T (pt) 2018-01-15
EP3099688B1 (en) 2017-10-18
US20170057961A1 (en) 2017-03-02
JP2017504640A (ja) 2017-02-09
LT3099688T (lt) 2017-12-27
TWI703144B (zh) 2020-09-01
WO2015116882A1 (en) 2015-08-06
CN106459051B (zh) 2018-10-16
DK3099688T3 (en) 2018-01-15
BR112016016741A2 (US07585860-20090908-C00136.png) 2017-08-08
CA2937738A1 (en) 2015-08-06
HUE038060T2 (hu) 2018-09-28
PL3099688T3 (pl) 2018-03-30
EA032650B1 (ru) 2019-06-28
MX2016009385A (es) 2016-09-16
JP6419836B2 (ja) 2018-11-07
BR112016016741B1 (pt) 2023-01-17
UY35972A (es) 2015-07-31
CN106459051A (zh) 2017-02-22
US10273236B2 (en) 2019-04-30
CY1120534T1 (el) 2019-07-10
EP3099688A1 (en) 2016-12-07
AR099228A1 (es) 2016-07-06

Similar Documents

Publication Publication Date Title
BR112014017635A2 (US07585860-20090908-C00136.png)
BR112014018355A2 (US07585860-20090908-C00136.png)
BR112014019238A2 (US07585860-20090908-C00136.png)
BR112014017592A2 (US07585860-20090908-C00136.png)
BR112014017659A2 (US07585860-20090908-C00136.png)
BR112014017646A2 (US07585860-20090908-C00136.png)
BR112014017638A2 (US07585860-20090908-C00136.png)
AR092201A1 (US07585860-20090908-C00136.png)
BR112014023727A2 (US07585860-20090908-C00136.png)
NO2760821T3 (US07585860-20090908-C00136.png)
BR112013027865A2 (US07585860-20090908-C00136.png)
BR112014018304A2 (US07585860-20090908-C00136.png)
BR112014017634A2 (US07585860-20090908-C00136.png)
BR112014017644A2 (US07585860-20090908-C00136.png)
BR112014017647A2 (US07585860-20090908-C00136.png)
BR112014017588A2 (US07585860-20090908-C00136.png)
BR112014022171A2 (US07585860-20090908-C00136.png)
BR112014013184A8 (US07585860-20090908-C00136.png)
BR112014017652A2 (US07585860-20090908-C00136.png)
BR112014018814A2 (US07585860-20090908-C00136.png)
BR112014017641A2 (US07585860-20090908-C00136.png)
BR112014021172A2 (US07585860-20090908-C00136.png)
BR112014020009A2 (US07585860-20090908-C00136.png)
BR112014017636A2 (US07585860-20090908-C00136.png)
BR112014019199A2 (US07585860-20090908-C00136.png)